Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antibody combined with cancer drug shows promise against breast tumors

17.05.2005


An antibody that targets the blood vessels nourishing tumors significantly reduced breast cancer formation and growth in mice when combined with a current cancer drug, according to researchers at UT Southwestern Medical Center. Their work appears in today’s issue of Cancer Research.



"This antibody could enhance the therapeutic efficacy of the drug docetaxel in breast cancer patients," said Dr. Philip Thorpe, professor of pharmacology at UT Southwestern and senior author of the research. "The combination merits further scrutiny as a potential treatment for human cancer." Docetaxel is one of the most effective chemotherapeutic drugs for treating breast, ovarian and prostate cancer, but its use in treating other cancers is limited by its toxicity.

In their study of mice, Drs. Thorpe and Xianming Huang, assistant professor of pharmacology in the Harold C. Simmons Comprehensive Cancer Center, found the antibody compound 3G4 was effective as a vascular targeting agent (VTA) when used with docetaxel. VTAs are designed to find and destroy blood vessels within cancerous tumors, cutting off their blood supply.


Specifically, mice with human breast tumors treated with 3G4 and docetaxel had a 93 percent reduction in overall tumor growth. The injected breast cancer cells also stimulated the growth of tumor colonies in the lungs, and the drug combination reduced the average number of those colonies by 93 percent, with half of the mice not developing any lung tumors.

The combination of 3G4 and docetaxel was much better than either compound used by itself, Dr. Thorpe said. In mice with breast cancer tumors, growth was suppressed by 50 percent using 3G4 alone and 70 percent for docetaxal alone. The reduction in lung tumor colonies was 82 percent with 3G4 alone and 78 percent with docetaxal alone.

Peregrine Pharmaceuticals is developing a version of 3G4 called Tarvacin for cancer treatment and recently received approval from the Food and Drug Administration for a phase I clinical trial. The compound was discovered by Dr. Thorpe’s lab, and Peregrine has a sponsored research agreement with UT Southwestern to further develop the drug. "We are currently investigating whether the enhanced therapeutic efficacy with 3G4 and docetaxel extends to other tumor models and other conventional therapies," Dr. Thorpe said.

VTAs like 3G4 target tumor vessels by selectively binding to a certain component in the membranes of endothelial cells that line tumor blood vessels. This component, called an anionic phospholipid, faces the interior of cells in normal blood vessels. In tumor blood vessels, however, changes in the tumor environment cause the phospholipid to flip inside out and be positioned on the external surface. VTAs then can bind to this exposed phospholipid, causing the body’s white cells to attack and destroy the vessels feeding the tumor.

By targeting receptors unique to tumor vessels, vascular targeting agents kill tumors without causing damage to surrounding healthy tissue. They also reduce the risk of side effects by operating at lower doses than traditional cancer therapies because they are effective without needing to penetrate the innermost layer of a tumor.

And, while drug resistance caused by the instability and mutability of cancer cells is a significant problem with conventional therapies that target tumor cells, cells targeted by VTAs do not mutate to become drug resistant, Dr. Thorpe said.

Tarvacin itself has shown promise in mice against cancers in the fibrous tissues, brain cancers and Hodgkin’s disease.

Mary Bennett, a UT Southwestern technician, also contributed to the Cancer Research study.

Toni Heinzl | EurekAlert!
Further information:
http://www.utsouthwestern.edu

More articles from Life Sciences:

nachricht Rainbow colors reveal cell history: Uncovering β-cell heterogeneity
22.09.2017 | DFG-Forschungszentrum für Regenerative Therapien TU Dresden

nachricht The pyrenoid is a carbon-fixing liquid droplet
22.09.2017 | Max-Planck-Institut für Biochemie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Rainbow colors reveal cell history: Uncovering β-cell heterogeneity

22.09.2017 | Life Sciences

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>